CordenPharma’s Drug Product Innovation Centre of Excellence in CordenPharma Plankstadt (DE).
CordenPharma is pleased to announce the opening of a Drug Product Innovation Centre of Excellence with new Bioavailability Enhancement capabilities for the manufacturing of Oral Solid Dosage (OSD) Drug Products that contain low bioavailability APIs at our CordenPharma Plankstadt facility located near Heidelberg, Germany.
These new Bioavailability Enhancement capabilities were added in response to our customers’ demands and the recognition of gaps in formulation technologies for solubility-challenged APIs. Already equipped with conventional small scale OSD development processes including blending, granulation, compression, coating, and a tablet simulator, CordenPharma’s Drug Product Innovation Centre has added spray drying, hot melt extrusion, nanomilling, and micronization technologies. In addition, utilization of Lipid Excipients integrated from our Lipids Platform in SEDDS/SMEDDS formulations can address permeability issues. The Centre is capable of handling multiple projects in parallel, with open capacity to start projects immediately.
“This is an extremely important and significant investment for CordenPharma’s Oral Solid Dose capabilities. Our goal is to be the leading CDMO for the development and manufacturing of highly potent and non-potent solid dosage forms. Adding these enabling technologies to our toolbox allows us to help more customers that have bioavailability challenges with solubility-limited APIs. We are excited about this investment in Plankstadt, as it strengthens our core capabilities and expands our service offerings,” states Dr. Brittany Hayes, Director of CordenPharma’s Global Highly Potent & Oncology Platform.
“This is an extremely important and significant investment for CordenPharma’s Oral Solid Dose capabilities. Our goal is to be the leading CDMO for the development and manufacturing of highly potent and non-potent solid dosage forms. Adding these enabling technologies to our toolbox allows us to help more customers that have bioavailability challenges with solubility-limited APIs. We are excited about this investment in Plankstadt, as it strengthens our core capabilities and expands our service offerings,” states Dr. Brittany Hayes, Director of CordenPharma’s Global Highly Potent & Oncology Platform.
Contact Us for more information on Bioavailability Enhancement of solubility-challenged APIs for OSD Drug Product manfucturing.
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.